CURE’s skin cancer page is an extensive resource of cancer information featuring the latest skin cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on skin cancer.
December 13th 2024
Unloxcyt was approved by the FDA as a new treatment for patients with locally advanced or metastatic cutaneous squamous cell carcinoma.
FDA Grants Keytruda Priority Review to Treat Rare Form of Skin Cancer
September 4th 2018The Food and Drug Administration (FDA) granted priority review to a new supplemental biologics license application for Keytruda (pembrolizumab) to treat adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma, according to Merck, the agent’s manufacturer.
High Frequency of Common Skin Cancer May Warrant More Intensive Cancer Screening
August 15th 2018Individuals diagnosed with a high frequency of basal cell carcinomas, a common type of skin cancer, may be at an increased for developing an unrelated cancer, highlighting the need for additional clinical screening.
Cancer Rates 'Soar' in Flight Crew Compared with General Population
July 4th 2018While having a career as a flight attendant allows individuals to travel the globe, exposure to carcinogens and frequent disruptions in circadian rhythms may increase cancer prevalence in these individuals, according to recent research published in the journal Environmental Health.
FDA Approves Drug Duo for BRAF-Positive Melanoma
June 27th 2018The FDA has approved the combination of the BRAF inhibitor Braftovi (encorafenib) and the MEK inhibitor Mektovi (binimetinib) for the treatment of patients with BRAF-mutant unresectable or metastatic melanoma, as detected by an FDA-approved test.
Keytruda Granted sBLA for Melanoma Treatment
June 25th 2018The FDA has accepted a supplemental biologics license application (sBLA) for the use of Keytruda (pembrolizumab) as an adjuvant treatment for patients with resected, high-risk stage 3 melanoma, according to Merck (MSD), the manufacturer of the PD-1 inhibitor.
Testing Only the 'Tip of the Iceberg' for Common Hereditary Condition in MSI-H Tumors
June 14th 2018Lynch syndrome – a hereditary condition that increases a person’s risk for developing several types of cancer – is common among people with microsatellite instability-high (MSI-H) tumors, linking it to several new cancer types, according to large genomic study results presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
Larotrectinib Granted Priority Review for NTRK-Positive Cancers
May 29th 2018The FDA has granted a priority review to a new drug application (NDA) for larotrectinib for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors with an NTRK gene fusion, according to Bayer and Loxo Oncology, the codevelopers of the pan-TRK inhibitor.
Patients and Caregivers Are on the 'Frontline' of Melanoma Monitoring
May 22nd 2018Recent research, conducted at NYU Langone Health and presented at the Oncology Nursing Society (ONS) Annual Congress, sought to find out how patients with melanoma perceived skin health education, and their willingness be involved in their own surveillance or a loved one’s.